MedTrace Logo

Investigation of Genetic Determinants of Capecitabine Toxicity

NCT00977119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2024-07-31

No results posted yet for this study

Summary

The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia).

Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.

Conditions

Interventions

OTHER

Side-effect questionnaires

Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly

OTHER

research blood samples

Blood samples for research on DNA before starting treatment and after 4 cycles of treatment

Sponsors & Collaborators

  • Translational Breast Cancer Research Consortium

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Peter H O'Donnell, MD · University of Chicago

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-23
Primary Completion
2021-06-21
Completion
2021-06-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977119 on ClinicalTrials.gov